However, interestingly, clinical trial on the use of bimagrumab, a monoclonal antibody against activin type II receptors that prevents binding of activin and myostatin, did not provide clinical benefits in terms of improvement in mobility in patients with inclusion body myositis [105]. This evidence concerns the gene MSTN and inclusion body myositis.